Integrated Prognostic Score in Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel - A CABASTY Post Hoc Analysis Validated by Two International Prospective Phase 3 Trials
{{output}}
Background and objective: Optimal therapy after docetaxel and an androgen receptor pathway inhibitor (ARPI) in metastatic castration-resistant prostate cancer (mCRPC) remains debated. We aimed to build and validate the cabascore,... ...
